Novel ADC Achieves Impressive PFS Advantage in HER2-Low Metastatic Breast Cancer

(MedPage Today) -- Patients with recurrent or metastatic HER2-low breast cancer had dramatic improvement in progression-free survival (PFS) when treated with a novel antibody-drug conjugate (ADC) targeting HER2, a large randomized trial showed...